NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…
Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?
(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say. Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned…
AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial
(Reuters)—U.S. drugmaker AbbVie Inc said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments. Two doses of the drug, upadacitinib, induced a statistically significant reduction in symptoms compared to a placebo in the 12-week long study,…
Anti-Drug Antibodies May Affect RA Treatment
A recent study examined the level of anti-drug antibodies (ADAs) in RA patients taking the TNF inhibitors adalimumab, infliximab and etanercept. Study patients without ADAs experienced better clinical outcomes, while patients with detectable ADAs had significantly lower serum trough drug concentrations…
Older Adults May Stave Off Arthritis Knee Pain with Fiber
(Reuters Health)—Older people who eat the most fiber are at lower risk of developing knee pain and stiffness due to osteoarthritis (OA), new research shows.1 Diets rich in fiber from plant-based foods have clear health benefits, such as lower cholesterol, better-controlled blood sugar and a healthier weight, but most people in the U.S. don’t eat…
Voclosporin Promising for Lupus Nephritis
In a recent clinical trial, voclosporin proved safe and effective at both low and high doses as a treatment for lupus nephritis…
Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease
New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…
Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails
NEW YORK (Reuters Health)—The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial. The SPIRIT-P2 trial joins the earlier phase 3 SPIRIT-P1 trial, which showed that ixekizumab was safe and effective in PsA patients not previously treated…
BAFF: A Fulcrum Between Resistance to Infection & Autoimmunity
New research has linked a TNFSF13B variant and B cell activating factor (BAFF), a common therapeutic target, with multiple sclerosis and systemic lupus erythematosus. The variant is a disease-risk allele associated with increased levels of soluble BAFF…
The Biomarkers of Lupus Disease Study
Most SLE clinical trials continue standard background medications being taken by patients at entry, based on assumptions that this minimizes the risk of serious flares and that immunologic interference is minimal. These assumptions are not evidence based, but eliminating polypharmacy in trials studying patients with active lupus remains controversial. These researchers tested the withdrawal of immunosuppressants to make SLE trial results more interpretable…
- « Previous Page
- 1
- …
- 188
- 189
- 190
- 191
- 192
- …
- 339
- Next Page »